We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncolytics Biotech Completes Initial Scale up of Manufacturing Process for REOLYSIN®
News

Oncolytics Biotech Completes Initial Scale up of Manufacturing Process for REOLYSIN®

Oncolytics Biotech Completes Initial Scale up of Manufacturing Process for REOLYSIN®
News

Oncolytics Biotech Completes Initial Scale up of Manufacturing Process for REOLYSIN®

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncolytics Biotech Completes Initial Scale up of Manufacturing Process for REOLYSIN®"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oncolytics Biotech Inc. has announced that it has successfully completed initial scale up of its manufacturing process for REOLYSIN®.

The process improvements and scale up to 40-litre batch size has resulted in increased total yields, which are a result of advancements in the media formulation used in the primary production of REOLYSIN® and in the downstream processing steps required to generate finished product.

The proprietary media formulation was developed by SAFC Biosciences, of Lenexa, Kansas. The scale up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI) located in Montreal, Canada.

The process at this scale now yields at least 20,000 doses at the maximum clinical dose for intravenous use, or 60,000 doses for local use. Further increases in scale are being investigated. "This enhanced manufacturing process will allow us to keep pace with our rapidly expanding clinical program for REOLYSIN®," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

Advertisement